{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:28:57Z","timestamp":1790983737472,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1007\/s10555-009-9195-6","type":"journal-article","created":{"date-parts":[[2009,12,4]],"date-time":"2009-12-04T05:20:40Z","timestamp":1259904040000},"page":"345-353","source":"Crossref","is-referenced-by-count":51,"title":["The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette\u2013Gu\u00e9rin (BCG) immunotherapy for urothelial carcinoma of the bladder"],"prefix":"10.1007","volume":"28","author":[{"given":"Henry M.","family":"Rosevear","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Lightfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,12,5]]},"reference":[{"key":"9195_CR1","first-page":"71","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., et al. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58, 71\u201396.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"9195_CR2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/03008880802285032","volume":"42","author":"DM Parkin","year":"2008","unstructured":"Parkin, D. M. (2008). The global burden of urinary bladder cancer. Scandinavian Journal of Urology and Nephrology Supplementum, 42, 12\u201320.","journal-title":"Scandinavian Journal of Urology and Nephrology Supplementum"},{"key":"9195_CR3","first-page":"225","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59, 225\u2013249.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"9195_CR4","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1289\/ehp.94102590","volume":"102","author":"H Vainio","year":"1994","unstructured":"Vainio, H., Heseltine, E., & Wilbourn, J. (1994). Priorities for future IARC monographs on the evaluation of carcinogenic risks to humans. Environmental Health Perspectives, 102, 590\u2013591.","journal-title":"Environmental Health Perspectives"},{"key":"9195_CR5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","volume":"66","author":"Z Kirkali","year":"2005","unstructured":"Kirkali, Z., Chan, T., Manoharan, M., Algaba, F., Busch, C., Cheng, L., et al. (2005). Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology, 66, 4\u201334.","journal-title":"Urology"},{"key":"9195_CR6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eururo.2004.03.017","volume":"46","author":"A Lopez-Beltran","year":"2004","unstructured":"Lopez-Beltran, A., & Montironi, R. (2004). Non-invasive urothelial neoplasms: According to the most recent WHO classification. European Urology, 46, 170\u2013176.","journal-title":"European Urology"},{"key":"9195_CR7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/106689690501300203","volume":"13","author":"R Montironi","year":"2005","unstructured":"Montironi, R., & Lopez-Beltran, A. (2005). The 2004 WHO classification of bladder tumors: A summary and commentary. International Journal of Surgical Pathology, 13, 143\u2013153.","journal-title":"International Journal of Surgical Pathology"},{"key":"9195_CR8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2006.01.037","volume":"67","author":"VE Reuter","year":"2006","unstructured":"Reuter, V. E. (2006). The pathology of bladder cancer. Urology, 67, 11\u201317. discussion 17\u201318.","journal-title":"Urology"},{"key":"9195_CR9","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/j.1464-410X.2006.06445.x","volume":"98","author":"M Pavone-Macaluso","year":"2006","unstructured":"Pavone-Macaluso, M., Lopez-Beltran, A., Aragona, F., Bassi, P., & Fitzpatrick, J. M. (2006). The pathology of bladder cancer: An update on selected issues. BJU International, 98, 1161\u20131165.","journal-title":"BJU International"},{"key":"9195_CR10","first-page":"683","volume":"40","author":"H Kretschmer","year":"1925","unstructured":"Kretschmer, H. (1925). Haematuria: A clinical study based on 933 consecutive cases. Surgery, Gynecology and Obstetrics, 40, 683\u2013686.","journal-title":"Surgery, Gynecology and Obstetrics"},{"key":"9195_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/jcp.2007.049312","volume":"61","author":"R Montironi","year":"2008","unstructured":"Montironi, R., Mazzucchelli, R., Scarpelli, M., Lopez-Beltran, A., & Cheng, L. (2008). Morphological diagnosis of urothelial neoplasms. Journal of Clinical Pathology, 61, 3\u201310.","journal-title":"Journal of Clinical Pathology"},{"key":"9195_CR12","volume-title":"World health organization classification of tumors: Pathology and genetics of tumors of the urinary system and male genital organs","author":"J Eble","year":"2004","unstructured":"Eble, J. (2004). World health organization classification of tumors: Pathology and genetics of tumors of the urinary system and male genital organs. Lyons: IARC."},{"key":"9195_CR13","volume-title":"Campbell-Walsh urology","author":"EA Klein","year":"2007","unstructured":"Klein, E. A., et al. (2007). Epidemiology, etiology, and prevention of prostate cancer. In A. J. Wein, et al. (Eds.), Campbell-Walsh urology. Philadelphia: Saunders."},{"key":"9195_CR14","first-page":"269","volume":"48","author":"MJ Droller","year":"1998","unstructured":"Droller, M. J. (1998). Bladder cancer: State-of-the-art care. CA: A Cancer Journal for Clinicians, 48, 269\u2013284.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"9195_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-5347(17)52738-X","volume":"128","author":"KW Kaye","year":"1982","unstructured":"Kaye, K. W., & Lange, P. H. (1982). Mode of presentation of invasive bladder cancer: Reassessment of the problem. Journal of Urology, 128, 31\u201333.","journal-title":"Journal of Urology"},{"key":"9195_CR16","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-03-1327","volume":"106","author":"TJ Kemp","year":"2005","unstructured":"Kemp, T. J., Ludwig, A. T., Earel, J. K., Moore, J. M., Vanoosten, R. L., Moses, B., et al. (2005). Neutrophil stimulation with Mycobacterium bovis bacillus Calmette\u2013Guerin (BCG) results in the release of functional soluble TRAIL\/Apo-2L. Blood, 106, 3474\u20133482.","journal-title":"Blood"},{"key":"9195_CR17","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","volume":"21","author":"MF Botteman","year":"2003","unstructured":"Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B., & Hauser, R. (2003). The health economics of bladder cancer: A comprehensive review of the published literature. Pharmacoeconomics, 21, 1315\u20131330.","journal-title":"Pharmacoeconomics"},{"key":"9195_CR18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/jnci\/djp039","volume":"101","author":"BK Hollenbeck","year":"2009","unstructured":"Hollenbeck, B. K., Ye, Z., Dunn, R. L., Montie, J. E., & Birkmeyer, J. D. (2009). Provider treatment intensity and outcomes for patients with early-stage bladder cancer. Journal of the National Cancer Institute, 101, 571\u2013580.","journal-title":"Journal of the National Cancer Institute"},{"key":"9195_CR19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","volume":"116","author":"A Morales","year":"1976","unstructured":"Morales, A., Eidinger, D., & Bruce, A. W. (1976). Intracavitary bacillus Calmette\u2013Guerin in the treatment of superficial bladder tumors. Journal of Urology, 116, 180\u2013183.","journal-title":"Journal of Urology"},{"key":"9195_CR20","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/S0022-5347(01)63160-4","volume":"159","author":"AS Belldegrun","year":"1998","unstructured":"Belldegrun, A. S., Franklin, J. R., O'Donnell, M. A., Gomella, L. G., Klein, E., Neri, R., et al. (1998). Superficial bladder cancer: The role of interferon-alpha. Journal of Urology, 159, 1793\u20131801.","journal-title":"Journal of Urology"},{"key":"9195_CR21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00002371-200307000-00006","volume":"26","author":"GR Weiss","year":"2003","unstructured":"Weiss, G. R., O'Donnell, M. A., Loughlin, K., Zonno, K., Laliberte, R. J., & Sherman, M. L. (2003). Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. Journal of Immunotherapy, 26, 343\u2013348.","journal-title":"Journal of Immunotherapy"},{"key":"9195_CR22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","volume":"24","author":"FN Joudi","year":"2006","unstructured":"Joudi, F. N., Smith, B. J., & O'Donnell, M. A. (2006). Final results from a national multicenter phase II trial of combination bacillus Calmette\u2013Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urologic Oncology, 24, 344\u2013348.","journal-title":"Urologic Oncology"},{"key":"9195_CR23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","volume":"54","author":"M Babjuk","year":"2008","unstructured":"Babjuk, M., Oosterlinck, W., Sylvester, R., Kaasinen, E., Bohle, A., & Palou-Redorta, J. (2008). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. European Urology, 54, 303\u2013314.","journal-title":"European Urology"},{"key":"9195_CR24","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.1988.6.9.1450","volume":"6","author":"HW Herr","year":"1988","unstructured":"Herr, H. W., Laudone, V. P., Badalament, R. A., Oettgen, H. F., Sogani, P. C., Freedman, B. D., et al. (1988). Bacillus Calmette\u2013Guerin therapy alters the progression of superficial bladder cancer. Journal of Clinical Oncology, 6, 1450\u20131455.","journal-title":"Journal of Clinical Oncology"},{"key":"9195_CR25","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0022-5347(01)65396-5","volume":"156","author":"A Pawinski","year":"1996","unstructured":"Pawinski, A., Sylvester, R., Kurth, K. H., Bouffioux, C., van der Meijden, A., Parmar, M. K., et al. (1996). A combined analysis of European organization for research and treatment of cancer, and medical research council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. Journal of Urology, 156, 1934\u20131940. discussion 1940\u20131931.","journal-title":"Journal of Urology"},{"key":"9195_CR26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","volume":"174","author":"RJ Sylvester","year":"2005","unstructured":"Sylvester, R. J., van der Meijden, A. P., Witjes, J. A., & Kurth, K. (2005). Bacillus Calmette\u2013Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials. Journal of Urology, 174, 86\u201391. discussion 91\u201382.","journal-title":"Journal of Urology"},{"key":"9195_CR27","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1200\/JCO.1995.13.6.1404","volume":"13","author":"HW Herr","year":"1995","unstructured":"Herr, H. W., Schwalb, D. M., Zhang, Z. F., Sogani, P. C., Fair, W. R., Whitmore, W. F., Jr., et al. (1995). Intravesical bacillus Calmette\u2013Guerin therapy prevents tumor progression and death from superficial bladder cancer: Ten-year follow-up of a prospective randomized trial. Journal of Clinical Oncology, 13, 1404\u20131408.","journal-title":"Journal of Clinical Oncology"},{"key":"9195_CR28","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","volume":"178","author":"MC Hall","year":"2007","unstructured":"Hall, M. C., Chang, S. S., Dalbagni, G., Pruthi, R. S., Seigne, J. D., Skinner, E. C., et al. (2007). Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. Journal of Urology, 178, 2314\u20132330.","journal-title":"Journal of Urology"},{"key":"9195_CR29","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/01.mou.0000240312.16324.9a","volume":"16","author":"PE Spiess","year":"2006","unstructured":"Spiess, P. E., & Grossman, H. B. (2006). Fluorescence cystoscopy: Is it ready for use in routine clinical practice? Current Opinion in Urology, 16, 372\u2013376.","journal-title":"Current Opinion in Urology"},{"key":"9195_CR30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0022-5347(01)66559-5","volume":"155","author":"M Kriegmair","year":"1996","unstructured":"Kriegmair, M., Baumgartner, R., Knuchel, R., Stepp, H., Hofstadter, F., & Hofstetter, A. (1996). Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. Journal of Urology, 155, 105\u2013109. discussion 109\u2013110.","journal-title":"Journal of Urology"},{"key":"9195_CR31","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0094-0143(21)00424-9","volume":"19","author":"DL Lamm","year":"1992","unstructured":"Lamm, D. L. (1992). Long-term results of intravesical therapy for superficial bladder cancer. Urologic Clinics of North America, 19, 573\u2013580.","journal-title":"Urologic Clinics of North America"},{"key":"9195_CR32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A Bohle","year":"2003","unstructured":"Bohle, A., Jocham, D., & Bock, P. R. (2003). Intravesical bacillus Calmette\u2013Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. Journal of Urology, 169, 90\u201395.","journal-title":"Journal of Urology"},{"key":"9195_CR33","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm, D. L., van der Meijden, P. M., Morales, A., Brosman, S. A., Catalona, W. J., Herr, H. W., et al. (1992). Incidence and treatment of complications of bacillus Calmette\u2013Guerin intravesical therapy in superficial bladder cancer. Journal of Urology, 147, 596\u2013600.","journal-title":"Journal of Urology"},{"key":"9195_CR34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1092-9134(98)80034-8","volume":"2","author":"R Bhan","year":"1998","unstructured":"Bhan, R., Pisharodi, L. R., Gudlaugsson, E., & Bedrossian, C. (1998). Cytological, histological, and clinical correlations in intravesical bacillus Calmette\u2013Guerin immunotherapy. Annals of Diagnostic Pathology, 2, 55\u201360.","journal-title":"Annals of Diagnostic Pathology"},{"key":"9195_CR35","unstructured":"Anonymous. (1998). Case records of the Massachusetts General Hospital Weekly Clinicopathological exercises Case 29. New England Journal of Medicine, 339, 831."},{"key":"9195_CR36","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/107327480000700512","volume":"7","author":"M Elkabani","year":"2000","unstructured":"Elkabani, M., Greene, J. N., Vincent, A. L., VanHook, S., & Sandin, R. L. (2000). Disseminated Mycobacterium bovis after intravesicular bacillus Calmette\u2013Gu\u00e9rin treatments for bladder cancer. Cancer Control: Journal of the Moffitt Cancer Center, 7, 476\u2013481.","journal-title":"Cancer Control: Journal of the Moffitt Cancer Center"},{"key":"9195_CR37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/SMJ.0b013e31815d4047","volume":"101","author":"KA Nadasy","year":"2008","unstructured":"Nadasy, K. A., Patel, R. S., Emmett, M., Murillo, R. A., Tribble, M. A., Black, R. D., et al. (2008). Four cases of disseminated Mycobacterium bovis infection following intravesical BCG instillation for treatment of bladder carcinoma. Southern Medical Journal, 101, 91\u201395.","journal-title":"Southern Medical Journal"},{"key":"9195_CR38","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0090-4295(01)00921-9","volume":"57","author":"F Saint","year":"2001","unstructured":"Saint, F., Patard, J. J., Irani, J., Salomon, L., Hoznek, A., Legrand, P., et al. (2001). Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology, 57, 617\u2013621. discussion 621\u2013612.","journal-title":"Urology"},{"key":"9195_CR39","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0022-5347(17)42723-6","volume":"139","author":"RJ Torrence","year":"1988","unstructured":"Torrence, R. J., Kavoussi, L. R., Catalona, W. J., & Ratliff, T. L. (1988). Prognostic factors in patients treated with intravesical bacillus Calmette\u2013Guerin for superficial bladder cancer. Journal of Urology, 139, 941\u2013944.","journal-title":"Journal of Urology"},{"key":"9195_CR40","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00262-003-0384-9","volume":"52","author":"E Watanabe","year":"2003","unstructured":"Watanabe, E., Matsuyama, H., Matsuda, K., Ohmi, C., Tei, Y., Yoshihiro, S., et al. (2003). Urinary interleukin-2 may predict clinical outcome of intravesical bacillus Calmette\u2013Guerin immunotherapy for carcinoma in situ of the bladder. Cancer Immunology and Immunotherapy, 52, 481\u2013486.","journal-title":"Cancer Immunology and Immunotherapy"},{"key":"9195_CR41","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","volume":"167","author":"F Saint","year":"2002","unstructured":"Saint, F., Patard, J. J., Maille, P., Soyeux, P., Hoznek, A., Salomon, L., et al. (2002). Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette\u2013Guerin treatment for superficial bladder cancer. Journal of Urology, 167, 364\u2013367.","journal-title":"Journal of Urology"},{"key":"9195_CR42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","volume":"14","author":"Y Shintani","year":"2007","unstructured":"Shintani, Y., Sawada, Y., Inagaki, T., Kohjimoto, Y., Uekado, Y., & Shinka, T. (2007). Intravesical instillation therapy with bacillus Calmette\u2013Guerin for superficial bladder cancer: Study of the mechanism of bacillus Calmette\u2013Guerin immunotherapy. International Journal of Urology, 14, 140\u2013146.","journal-title":"International Journal of Urology"},{"key":"9195_CR43","volume-title":"Cancer nursing","author":"C Yarbro","year":"2006","unstructured":"Yarbro, C., Frogge, M., & Goodman, M. (2006). Cancer nursing: Principles and practice, 6th edn. Sudburry, Massachusetts: Jones and Bartlett Publishers."},{"key":"9195_CR44","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-04-0374","volume":"64","author":"AT Ludwig","year":"2004","unstructured":"Ludwig, A. T., Moore, J. M., Luo, Y., Chen, X., Saltsgaver, N. A., O'Donnell, M. A., et al. (2004). Tumor necrosis factor-related apoptosis-inducing ligand: A novel mechanism for bacillus Calmette\u2013Guerin-induced antitumor activity. Cancer Research, 64, 3386\u20133390.","journal-title":"Cancer Research"},{"key":"9195_CR45","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1074\/jbc.274.8.4521","volume":"274","author":"W Zhao","year":"1999","unstructured":"Zhao, W., Schorey, J. S., Groger, R., Allen, P. M., Brown, E. J., & Ratliff, T. L. (1999). Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP. Journal of Biological Chemistry, 274, 4521\u20134526.","journal-title":"Journal of Biological Chemistry"},{"key":"9195_CR46","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI114434","volume":"85","author":"LR Kavoussi","year":"1990","unstructured":"Kavoussi, L. R., Brown, E. J., Ritchey, J. K., & Ratliff, T. L. (1990). Fibronectin-mediated Calmette\u2013Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. Journal of Clinical Investigation, 85, 62\u201367.","journal-title":"Journal of Clinical Investigation"},{"key":"9195_CR47","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0022-5347(17)38622-6","volume":"145","author":"MJ Becich","year":"1991","unstructured":"Becich, M. J., Carroll, S., & Ratliff, T. L. (1991). Internalization of bacille Calmette\u2013Guerin by bladder tumor cells. Journal of Urology, 145, 1316\u20131324.","journal-title":"Journal of Urology"},{"key":"9195_CR48","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1128\/CDLI.3.6.761-768.1996","volume":"3","author":"Y Luo","year":"1996","unstructured":"Luo, Y., Szilvasi, A., Chen, X., DeWolf, W. C., & O'Donnell, M. A. (1996). A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein. Clinical and Diagnostic Laboratory Immunology, 3, 761\u2013768.","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"issue":"Suppl 3","key":"9195_CR49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000052388","volume":"37","author":"DH Schamhart","year":"2000","unstructured":"Schamhart, D. H., de Boer, E. C., de Reijke, T. M., & Kurth, K. (2000). Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: Their practical use. European Urology, 37(Suppl 3), 16\u201323.","journal-title":"European Urology"},{"key":"9195_CR50","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","volume":"164","author":"GN Thalmann","year":"2000","unstructured":"Thalmann, G. N., Sermier, A., Rentsch, C., Mohrle, K., Cecchini, M. G., & Studer, U. E. (2000). Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette\u2013Guerin. Journal of Urology, 164, 2129\u20132133.","journal-title":"Journal of Urology"},{"key":"9195_CR51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00294021","volume":"19","author":"EC Boer de","year":"1991","unstructured":"de Boer, E. C., de Jong, W. H., van der Meijden, A. P., Steerenberg, P. A., Witjes, F., Vegt, P. D., et al. (1991). Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urologic Research, 19, 45\u201350.","journal-title":"Urologic Research"},{"key":"9195_CR52","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","volume":"155","author":"TM Reijke de","year":"1996","unstructured":"de Reijke, T. M., de Boer, E. C., Kurth, K. H., & Schamhart, D. H. (1996). Urinary cytokines during intravesical bacillus Calmette\u2013Guerin therapy for superficial bladder cancer: Processing, stability and prognostic value. Journal of Urology, 155, 477\u2013482.","journal-title":"Journal of Urology"},{"key":"9195_CR53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-5347(17)39366-7","volume":"144","author":"A Bohle","year":"1990","unstructured":"Bohle, A., Nowc, C., Ulmer, A. J., Musehold, J., Gerdes, J., Hofstetter, A. G., et al. (1990). Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette\u2013Guerin immunotherapy. Journal of Urology, 144, 59\u201364.","journal-title":"Journal of Urology"},{"key":"9195_CR54","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","volume":"99","author":"AM Jackson","year":"1995","unstructured":"Jackson, A. M., Alexandroff, A. B., Kelly, R. W., Skibinska, A., Esuvaranathan, K., Prescott, S., et al. (1995). Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette\u2013Guerin (BCG) immunotherapy. Clinical and Experimental Immunology, 99, 369\u2013375.","journal-title":"Clinical and Experimental Immunology"},{"key":"9195_CR55","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","volume":"162","author":"Y Luo","year":"1999","unstructured":"Luo, Y., Chen, X., Downs, T. M., DeWolf, W. C., & O'Donnell, M. A. (1999). IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette\u2013Guerin immunotherapy. Journal of Immunology, 162, 2399\u20132405.","journal-title":"Journal of Immunology"},{"key":"9195_CR56","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0952-7915(94)90119-8","volume":"6","author":"RJ Armitage","year":"1994","unstructured":"Armitage, R. J. (1994). Tumor necrosis factor receptor superfamily members and their ligands. Current Opinion in Immunology, 6, 407\u2013413.","journal-title":"Current Opinion in Immunology"},{"key":"9195_CR57","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/(SICI)1521-4141(199809)28:09<2714::AID-IMMU2714>3.0.CO;2-9","volume":"28","author":"MJ Martinez-Lorenzo","year":"1998","unstructured":"Martinez-Lorenzo, M. J., Alava, M. A., Gamen, S., Kim, K. J., Chuntharapai, A., Pineiro, A., et al. (1998). Involvement of APO2 ligand\/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. European Journal of Immunology, 28, 2714\u20132725.","journal-title":"European Journal of Immunology"},{"key":"9195_CR58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1074-7613(00)80100-4","volume":"11","author":"SS Cha","year":"1999","unstructured":"Cha, S. S., Kim, M. S., Choi, Y. H., Sung, B. J., Shin, N. K., Shin, H. C., et al. (1999). 2.8\u00a0A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity, 11, 253\u2013261.","journal-title":"Immunity"},{"key":"9195_CR59","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1097-2765(00)80207-5","volume":"4","author":"SG Hymowitz","year":"1999","unstructured":"Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R. F., et al. (1999). Triggering cell death: The crystal structure of Apo2L\/TRAIL in a complex with death receptor 5. Molecular Cell, 4, 563\u2013571.","journal-title":"Molecular Cell"},{"key":"9195_CR60","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1021\/bi992242l","volume":"39","author":"SG Hymowitz","year":"2000","unstructured":"Hymowitz, S. G., O'Connell, M. P., Ultsch, M. H., Hurst, A., Totpal, K., Ashkenazi, A., et al. (2000). A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L\/TRAIL. Biochemistry, 39, 633\u2013640.","journal-title":"Biochemistry"},{"key":"9195_CR61","doi-asserted-by":"crossref","first-page":"20632","DOI":"10.1074\/jbc.M909721199","volume":"275","author":"JL Bodmer","year":"2000","unstructured":"Bodmer, J. L., Meier, P., Tschopp, J., & Schneider, P. (2000). Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. Journal of Biological Chemistry, 275, 20632\u201320637.","journal-title":"Journal of Biological Chemistry"},{"key":"9195_CR62","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., et al. (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673\u2013682.","journal-title":"Immunity"},{"key":"9195_CR63","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","volume":"271","author":"RM Pitti","year":"1996","unstructured":"Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Journal of Biological Chemistry, 271, 12687\u201312690.","journal-title":"Journal of Biological Chemistry"},{"key":"9195_CR64","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.4049\/jimmunol.161.6.2833","volume":"161","author":"TS Griffith","year":"1998","unstructured":"Griffith, T. S., Chin, W. A., Jackson, G. C., Lynch, D. H., & Kubin, M. Z. (1998). Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. Journal of Immunology, 161, 2833\u20132840.","journal-title":"Journal of Immunology"},{"key":"9195_CR65","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.4049\/jimmunol.162.5.2597","volume":"162","author":"TS Griffith","year":"1999","unstructured":"Griffith, T. S., Rauch, C. T., Smolak, P. J., Waugh, J. Y., Boiani, N., Lynch, D. H., et al. (1999). Functional analysis of TRAIL receptors using monoclonal antibodies. Journal of Immunology, 162, 2597\u20132605.","journal-title":"Journal of Immunology"},{"key":"9195_CR66","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1074-7613(00)80399-4","volume":"7","author":"MA Degli-Esposti","year":"1997","unstructured":"Degli-Esposti, M. A., Dougall, W. C., Smolak, P. J., Waugh, J. Y., Smith, C. A., & Goodwin, R. G. (1997). The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity, 7, 813\u2013820.","journal-title":"Immunity"},{"key":"9195_CR67","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0952-7915(98)80224-0","volume":"10","author":"TS Griffith","year":"1998","unstructured":"Griffith, T. S., & Lynch, D. H. (1998). TRAIL: A molecule with multiple receptors and control mechanisms. Current Opinion in Immunology, 10, 559\u2013563.","journal-title":"Current Opinion in Immunology"},{"key":"9195_CR68","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","volume":"273","author":"JG Emery","year":"1998","unstructured":"Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., et al. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Journal of Biological Chemistry, 273, 14363\u201314367.","journal-title":"Journal of Biological Chemistry"},{"key":"9195_CR69","doi-asserted-by":"crossref","first-page":"5386","DOI":"10.1093\/emboj\/16.17.5386","volume":"16","author":"H Walczak","year":"1997","unstructured":"Walczak, H., Degli-Esposti, M. A., Johnson, R. S., Smolak, P. J., Waugh, J. Y., Boiani, N., et al. (1997). TRAIL-R2: A novel apoptosis-mediating receptor for TRAIL. EMBO Journal, 16, 5386\u20135397.","journal-title":"EMBO Journal"},{"key":"9195_CR70","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0022-5347(17)54303-7","volume":"127","author":"AS Pang","year":"1982","unstructured":"Pang, A. S., & Morales, A. (1982). BCG induced murine peritoneal exudate cells: Cytotoxic activity against a syngeneic bladder tumor cell line. Journal of Urology, 127, 1225\u20131229.","journal-title":"Journal of Urology"},{"key":"9195_CR71","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1084\/jem.191.7.1095","volume":"191","author":"K Song","year":"2000","unstructured":"Song, K., Chen, Y., Goke, R., Wilmen, A., Seidel, C., Goke, A., et al. (2000). Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. Journal of Experimental Medicine, 191, 1095\u20131104.","journal-title":"Journal of Experimental Medicine"},{"key":"9195_CR72","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni894","volume":"4","author":"SE Lamhamedi-Cherradi","year":"2003","unstructured":"Lamhamedi-Cherradi, S. E., Zheng, S. J., Maguschak, K. A., Peschon, J., & Chen, Y. H. (2003). Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL\u2212\/\u2212 mice. Nature Immunology, 4, 255\u2013260.","journal-title":"Nature Immunology"},{"key":"9195_CR73","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.2337\/diabetes.52.8.1967","volume":"52","author":"QS Mi","year":"2003","unstructured":"Mi, Q. S., Ly, D., Lamhamedi-Cherradi, S. E., Salojin, K. V., Zhou, L., Grattan, M., et al. (2003). Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice. Diabetes, 52, 1967\u20131975.","journal-title":"Diabetes"},{"key":"9195_CR74","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.2337\/diabetes.52.9.2274","volume":"52","author":"SE Lamhamedi-Cherradi","year":"2003","unstructured":"Lamhamedi-Cherradi, S. E., Zheng, S., Tisch, R. M., & Chen, Y. H. (2003). Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes. Diabetes, 52, 2274\u20132278.","journal-title":"Diabetes"},{"key":"9195_CR75","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/infdis\/156.6.985","volume":"156","author":"AE Brown","year":"1987","unstructured":"Brown, A. E., Holzer, T. J., & Andersen, B. R. (1987). Capacity of human neutrophils to kill mycobacterium tuberculosis. Journal of Infectious Disease, 156, 985\u2013989.","journal-title":"Journal of Infectious Disease"},{"key":"9195_CR76","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1128\/IAI.70.9.5322-5327.2002","volume":"70","author":"SA Fulton","year":"2002","unstructured":"Fulton, S. A., Reba, S. M., Martin, T. D., & Boom, W. H. (2002). Neutrophil-mediated mycobacteriocidal immunity in the lung during Mycobacterium bovis BCG infection in C57BL\/6 mice. Infection and Immunity, 70, 5322\u20135327.","journal-title":"Infection and Immunity"},{"key":"9195_CR77","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1128\/IAI.63.9.3381-3387.1995","volume":"63","author":"R Appelberg","year":"1995","unstructured":"Appelberg, R., Castro, A. G., Gomes, S., Pedrosa, J., & Silva, M. T. (1995). Susceptibility of beige mice to mycobacterium avium: Role of neutrophils. Infection and Immunity, 63, 3381\u20133387.","journal-title":"Infection and Immunity"},{"key":"9195_CR78","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1158\/0008-5472.CAN-03-1808","volume":"64","author":"Y Koga","year":"2004","unstructured":"Koga, Y., Matsuzaki, A., Suminoe, A., Hattori, H., & Hara, T. (2004). Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): A novel mechanism of antitumor effect by neutrophils. Cancer Research, 64, 1037\u20131043.","journal-title":"Cancer Research"},{"key":"9195_CR79","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.0019-2805.2003.01794.x","volume":"111","author":"H Kamohara","year":"2004","unstructured":"Kamohara, H., Matsuyama, W., Shimozato, O., Abe, K., Galligan, C., Hashimoto, S., et al. (2004). Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptor expression in human neutrophils. Immunology, 111, 186\u2013194.","journal-title":"Immunology"},{"key":"9195_CR80","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.juro.2008.11.124","volume":"181","author":"A Bisiaux","year":"2009","unstructured":"Bisiaux, A., Thiounn, N., Timsit, M. O., Eladaoui, A., Chang, H. H., Mapes, J., et al. (2009). Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus Calmette\u2013Guerin therapy in patients with superficial bladder cancer. Journal of Urology, 181, 1571\u20131580.","journal-title":"Journal of Urology"},{"key":"9195_CR81","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0140-6736(98)07422-4","volume":"353","author":"AB Alexandroff","year":"1999","unstructured":"Alexandroff, A. B., Jackson, A. M., O'Donnell, M. A., & James, K. (1999). BCG immunotherapy of bladder cancer: 20\u00a0years on. Lancet, 353, 1689\u20131694.","journal-title":"Lancet"},{"key":"9195_CR82","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1128\/IAI.00938-06","volume":"75","author":"MP Simons","year":"2007","unstructured":"Simons, M. P., Moore, J. M., Kemp, T. J., & Griffith, T. S. (2007). Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils. Infection and Immunity, 75, 1265\u20131271.","journal-title":"Infection and Immunity"},{"key":"9195_CR83","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1189\/jlb.69.6.1036","volume":"69","author":"BW Jones","year":"2001","unstructured":"Jones, B. W., Means, T. K., Heldwein, K. A., Keen, M. A., Hill, P. J., Belisle, J. T., et al. (2001). Different Toll-like receptor agonists induce distinct macrophage responses. Journal of Leukocyte Biology, 69, 1036\u20131044.","journal-title":"Journal of Leukocyte Biology"},{"key":"9195_CR84","doi-asserted-by":"crossref","first-page":"8250","DOI":"10.1158\/0008-5472.CAN-06-1416","volume":"66","author":"H Suttmann","year":"2006","unstructured":"Suttmann, H., Riemensberger, J., Bentien, G., Schmaltz, D., Stockle, M., Jocham, D., et al. (2006). Neutrophil granulocytes are required for effective bacillus Calmette\u2013Guerin immunotherapy of bladder cancer and orchestrate local immune responses. Cancer Research, 66, 8250\u20138257.","journal-title":"Cancer Research"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-009-9195-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10555-009-9195-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-009-9195-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T19:42:21Z","timestamp":1685216541000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10555-009-9195-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":84,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["9195"],"URL":"https:\/\/doi.org\/10.1007\/s10555-009-9195-6","relation":{},"ISSN":["0167-7659","1573-7233"],"issn-type":[{"value":"0167-7659","type":"print"},{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}